warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Roche GO29831: A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH TRASTUZUMAB EMTANSINE OR WITH TRASTUZUMAB AND PERTUZUMAB (WITH ANDWITHOUT DOCETAXEL) IN PATIENTS WITH H
Brief Description  
The primary safety objective for this study is to evaluate the safety and tolerability of the following combination treatments administered q3w to patients with HER2-positive MBC or operable LABC or inflammatory EBC: Atezolizumab in combination with trastuzumab and pertuzumab and Atezolizumab in combination with trastuzumab emtansine
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Breast - Female
Status  
OPEN
Start Date  
08/08/2016
IRB Number  
00017791
Principal Investigator  
Fisher, Julie Gottlieb
Contact Name  
Mandy Campbell

For More Information, Contact  Mandy  , Campbell
Phone:  980-442-2340 Fax:    
Email:  Amanda.Setzer@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close